trans health care, trans joy, resources for trans people, hormones, surgery, US Supreme Court, trans rights, healthcare access, Jules Gill-Peterson --- ## The Silent Struggles of Trans Individuals In the shadow of societal norms, where acceptance often feels like an unreachable dream, the journey of trans individuals is riddled with pain and longing. Each day, they navigate a world that...

Good News Colon cancer recurrence and deaths cut 28% by simple exercise, trial finds Any type of aerobic exercise works for the improvements, study finds. Beth Mole – Jun 2, 2025 6:05 pm | 42 Credit: Getty | Oli Kellett Credit: Getty | Oli Kellett Story text Size Small Standard Large Width * Standard Wide Links Standard Orange * Subscribers only   Learn more Exercise is generally good for you, but a new high-quality clinical trial finds that it's so good, it can even knock back colon cancer—and, in fact, rival some chemotherapy treatments. The finding comes from a phase 3, randomized clinical trial led by researchers in Canada, who studied nearly 900 people who had undergone surgery and chemotherapy for colon cancer. After those treatments, patients were evenly split into groups that either bulked up their regular exercise routines in a three-year program that included coaching and supervision or were simply given health education. The researchers found that the exercise group had a 28 percent lower risk of their colon cancer recurring, new cancers developing, or dying over eight years compared with the health education group. The benefits of exercise, published in the New England Journal of Medicine, became visible after just one year and increased over time, the researchers found. The rate of people who survived for five years and remained cancer-free was 80.3 percent among the exercise group. That's a 6.4 percentage-point survival boost over the education group, which had a 73.9 percent cancer-free survival rate. The overall survival rate (with or without cancer) during the study's eight-year follow-up was 90.3 percent in the exercise group compared with 83.2 percent in the education group—a 7.1 percentage point difference. Exercise reduced the relative risk of death by 37 percent (41 people died in the exercise group compared with 66 in the education group). "The magnitude of benefit from exercise ... was similar to that of many currently approved standard drug treatments," the researchers noted. However, the exercise routines that achieved those substantial benefits weren't heavy-duty. Participants were coached to perform any recreational aerobic exercise they enjoyed, including brisk walking. Adding 45- to 60-minute brisk walks three or four times a week, or three or four jogs lasting 25 to 30 minutes, was enough for many of the participants to improve their odds. Overall, the goal was to get the exercise group over 20 MET hours per week. METs are Metabolic Equivalents of Task, which represent the amount of energy your body is burning up compared to when you're at rest, sitting quietly. Brisk walking is about four METs, the researchers estimated, and jogging is around 10 METs. To get to 20 MET hours a week, a participant would have to do five hours of brisk walking a week (e.g., five hour-long walks a week) or jog for two hours a week (e.g., four 30-minute jogs per week). “Quite impressive” The exercise group, which had supervised exercise for the first six months of the three-year intervention, reported more exercise over the study. At the end, the exercise group was averaging over 20 MET hours per week, while the education group's average was around 15 MET hours per week. The exercise group also scored better at cardiorespiratory fitness and physical functioning. Still, with the health education, the control group also saw a boost to their exercise during the trial, with their average starting around 10 MET hours per week. These findings "raise the possibility of an even more powerful effect of exercise on cancer outcomes as compared with a completely sedentary control group," the researchers note. For now, it's not entirely clear how exercise keeps cancers at bay, but it squares with numerous other observational studies that have linked exercise to better outcomes in cancer patients. Researchers have several hypotheses, including that exercise might cause "increased fluid shear stress, enhanced immune surveillance, reduced inflammation, improved insulin sensitivity, and altered microenvironment of major sites of metastases," the authors note. In the study, exercise seemed to keep local and distant colon cancer from recurring, as well as prevent new cancers, including breast, prostate, and colorectal cancers. Outside experts hailed the study's findings. "This indicates that exercise has a similarly strong effect as previously shown for chemotherapy, which is really quite impressive," Marco Gerlinger, a gastrointestinal cancer expert at Queen Mary University of London, said in a statement. "One of the commonest questions from patients is what they can do to reduce the risk that their cancer comes back. Oncologists can now make a very clear evidence-based recommendation." "Having worked in bowel cancer research for 30 years, this is an exciting breakthrough in the step-wise improvement in cure rates," David Sebag-Montefiore, a clinical oncologist at the University of Leeds, said. "The great appeal of a structured moderate intensity exercise is that it offers the benefits without the downside of the well-known side effects of our other treatments." Beth Mole Senior Health Reporter Beth Mole Senior Health Reporter Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes. 42 Comments

Human organs could be bioprinted for transplants within 10 years, according to Lithuanian startup Vital3D. But before reaching human hearts and kidneys, the company is starting with something simpler: regenerating dog skin. Based in Vilnius, Vital3D is already bioprinting functional tissue constructs. Using a proprietary laser system, the startup deposits living cells and biomaterials in precise 3D patterns. The structures mimic natural biological systems — and could one day form entire organs tailored to a patient’s unique anatomy. That mission is both professional and personal for CEO Vidmantas Šakalys. After losing a mentor to urinary cancer, he set out to develop 3D-printed kidneys that could save others from the same fate. But before reaching that goal, the company needs a commercial product to fund the long road ahead. That product is VitalHeal — the first-ever bioprinted wound patch for pets. Dogs are the initial target, with human applications slated to follow. Šakalys calls the patch “a first step” towards bioprinted kidneys. “Printing organs for transplantation is a really challenging task,” he tells TNW after a tour of his lab. “It’s 10 or 15 years away from now, and as a commercial entity, we need to have commercially available products earlier. So we start with simpler products and then move into more difficult ones.” Register Now The path may be simpler, but the technology is anything but. Bioprinting goes to the vet VitalHeal is embedded with growth factors that accelerate skin regeneration. Across the patch’s surface, tiny pores about one-fifth the width of a human hair enable air circulation while blocking bacteria. Once applied, VitalHeal seals the wound and maintains constant pressure while the growth factors get to work. According to Vital3D, the patch can reduce healing time from 10–12 weeks to just four to six. Infection risk can drop from 30% to under 10%, vet visits from eight to two or three, and surgery times by half. Current treatments, the startup argues, can be costly, ineffective, and distressing for animals. VitalHeal is designed to provide a safer, faster, and cheaper alternative. Vital3D says the market is big — and the data backs up the claim. Vital3D’s FemtoBrush system promises high-speed and high-precision bioprinting. Credit: Vital3D Commercial prospects The global animal wound care market is projected to grow from $1.4bn (€1.24bn) in 2024 to $2.1bn (€1.87bn) by 2030, fuelled by rising pet ownership and demand for advanced veterinary care. Vital3D forecasts an initial serviceable addressable market (ISAM) of €76.5mn across the EU and US. By 2027-2028, the company aims to sell 100,000 units. Dogs are a logical starting point. Their size, activity levels, and surgeries raise their risk of wounds. Around half of dogs over age 10 are also affected by cancer, further increasing demand for effective wound care. At €300 retail (or €150 wholesale), the patches won’t be cheap. But Vital3D claims they could slash treatment costs for pet owners from €3,000 to €1,500. Production at scale is expected to bring prices down further.  After strong results in rats, trials on dogs will begin this summer in clinics in Lithuania and the UK — Vital3D’s pilot markets. If all goes to plan, a non-degradable patch will launch in Europe next year. The company will then progress to a biodegradable version. From there, the company plans to adapt the tech for humans. The initial focus will be wound care for people with diabetes, 25% of whom suffer from impaired healing. Future versions could support burn victims, injured soldiers, and others in need of advanced skin restoration. Freshly printed fluids in a bio-ink droplet. Credit: Vital3D Vital3D is also exploring other medical frontiers. In partnership with Lithuania’s National Cancer Institute, the startup is building organoids — mini versions of organs — for cancer drug testing. Another project involves bioprinted stents, which are showing promise in early animal trials. But all these efforts serve a bigger mission. “Our final target is to move to organ printing for transplants,” says Šakalys. Bioprinting organs A computer engineer by training, Šakalys has worked with photonic innovations for over 10 years.  At his previous startup, Femtika, he harnessed lasers to produce tiny components for microelectronics, medical devices, and aerospace engineering. He realised they could also enable precise bioprinting.  In 2021, he co-founded Vital3D to advance the concept. The company’s printing system directs light towards a photosensitive bio-ink. The material is hardened and formed into a structure, with living cells and biomaterials moulded into intricate 3D patterns. The shape of the laser beam can be adjusted to replicate complex biological forms — potentially even entire organs. But there are still major scientific hurdles to overcome. One is vascularisation, the formation of blood vessels in intricate networks. Another is the diverse variety of cell types in many organs. Replicating these sophisticated natural structures will be challenging. “First of all, we want to solve the vasculature. Then we will go into the differentiation of cells,” Šakalys says. “Our target is to see if we can print from fewer cells, but try to differentiate them while printing into different types of cells.”  If successful, Vital3D could help ease the global shortage of transplantable organs. Fewer than 10% of patients who need a transplant receive one each year, according to the World Health Organisation. In the US alone, around 90,000 people are waiting for a kidney — a shortfall that’s fuelling a thriving black market. Šakalys believes that could be just the start. He envisions bioprinting not just creating organs, but also advancing a new era of personalised medicine. “It can bring a lot of benefits to society,” he says. “Not just bioprinting for transplants, but also tissue engineering as well.” Want to discover the next big thing in tech? Then take a trip to TNW Conference, where thousands of founders, investors, and corporate innovators will share their ideas. The event takes place on June 19–20 in Amsterdam and tickets are on sale now. Use the code TNWXMEDIA2025 at the checkout to get 30% off. Story by Thomas Macaulay Managing editor Thomas is the managing editor of TNW. He leads our coverage of European tech and oversees our talented team of writers. Away from work, he e (show all) Thomas is the managing editor of TNW. He leads our coverage of European tech and oversees our talented team of writers. Away from work, he enjoys playing chess (badly) and the guitar (even worse). Get the TNW newsletter Get the most important tech news in your inbox each week. Also tagged with

You can trust VideoGamer. Our team of gaming experts spend hours testing and reviewing the latest games, to ensure you're reading the most comprehensive guide possible. Rest assured, all imagery and advice is unique and original. Check out how we test and review games here Tamriel Rebuilt is a massive mod for The Elder Scrolls III: Morrowind that adds mainland Morrowind to Bethesda’s 24-year-old RPG. Just a few weeks ago, the team released its biggest ever expansion dubbed Grasping Fortune which added the sprawling House Hlaalu capital city of Narsis. For the massive expansion, the team spent years designing a location bigger than any official Elder Scrolls city with over 600 building interiors. However, the team is already looking planning to make another expansion that’s “twice the size” of Grasping Fortune. Tamriel Rebuilt’s Indoril Heartland In an interview with PC Gamer, the team behind the massive Morrowind mod revealed their plans to tackle the Indoril heartland located outside of Almalexia, the capital city of Morrowind. When the team eventually gets to properly developing the city—which will probably be “in the next few years—it will be significantly bigger. “Almalexia is kind of like two cities, and just looking at our math, it’s about twice the size of Narsis,” said the mod’s project lead known as Cicero. “It might not be quite as dense as Narsis, just for our sanity and also for performance, but it’s gonna be twice as widespread, and it will have more buildings, for sure.” Additionally, the mod team will also have to perform digital surgery to connect their main construction of Almalexia with the outskirts of the city that were added in the original game’s Mournhold expansion. With the team not wanting to “delete anything”, there’s a significant amount of work to do, especially as the area is actually an interior in the base game. “You can’t really have that if you want to incorporate it into the actual mainland… it has to be implanted into Almalexia within the same worldspace, and things would have to be spread around,” the developer explained. With the team confident that a Morrowind Remake won’t be happening ever, there’s no pressure to rush out content. After over 20 years of development, there’s still a lot of work to be done on Tamriel Rebuilt, but every expansion is a massive, complete slice of the best Bethesda RPG created by fans. Maybe it’ll be finished by 2040. Subscribe to our newsletters! By subscribing, you agree to our Privacy Policy and may receive occasional deal communications; you can unsubscribe anytime. Share